Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

NCT01768559 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01768559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01768559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
December 31, 2014
Enrollment
894 (actual)
Sites
199

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes